$DMAC
DiaMedica Therapeutics Inc. Stock $dmac

$dmac Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-Q Financial Statement

#000143774922010876 Filed on May 04, 2022

Income Statement

Concept	2022 Q1	2021 Q1
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.562M	$1.210M
YoY Change	29.09%	18.63%
% of Gross Profit
Research & Development	$1.974M	$2.406M
YoY Change	-17.96%	78.35%
% of Gross Profit
Depreciation & Amortization	$6.000K	$6.000K
YoY Change	0.0%	0.0%
% of Gross Profit
Operating Expenses	$1.974M	$2.406M
YoY Change	-17.96%	78.35%
Operating Profit	-$3.536M	-$3.619M
YoY Change	-2.29%	50.54%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$35.00K	$4.000K
YoY Change	775.0%	-133.33%
Pretax Income	-$3.501M	-$3.615M
YoY Change	-3.15%	49.63%
Income Tax	$7.000K	$7.000K
% Of Pretax Income
Net Earnings	-$3.508M	-$3.622M
YoY Change	-3.15%	49.36%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.13	-$0.19
Diluted Earnings Per Share	-$132.7K	-$192.9K
COMMON SHARES
Basic Shares Outstanding	26.44M	18.77M
Diluted Shares Outstanding

Balance Sheet

Concept	2022 Q1	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$41.03M	$23.43M
YoY Change	75.13%	85.94%
Cash & Equivalents	$3.032M	$3.329M
Short-Term Investments	$38.00M	$20.10M
Other Short-Term Assets	$896.0K	$460.0K
YoY Change	94.78%	-14.81%
Inventory
Prepaid Expenses
Receivables	$168.0K	$337.0K
Other Receivables	$2.000K
Total Short-Term Assets	$42.11M	$24.20M
YoY Change	74.05%	70.81%
LONG-TERM ASSETS
Property, Plant & Equipment	$74.00K	$75.00K
YoY Change	-1.33%	25.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$100.0K	$161.0K
YoY Change	-37.89%	-19.5%
TOTAL ASSETS
Total Short-Term Assets	$42.11M	$24.20M
Total Long-Term Assets	$100.0K	$161.0K
Total Assets	$42.21M	$24.36M
YoY Change	73.31%	69.55%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$433.0K	$689.0K
YoY Change	-37.16%	55.18%
Accrued Expenses	$967.0K	$420.0K
YoY Change	130.24%	-3.45%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$6.000K	$10.00K
YoY Change	-40.0%	0.0%
Total Short-Term Liabilities	$1.434M	$1.178M
YoY Change	21.73%	25.99%
LONG-TERM LIABILITIES
Long-Term Debt	$9.000K	$10.00K
YoY Change	-10.0%	0.0%
Other Long-Term Liabilities		$30.00K
YoY Change		-70.0%
Total Long-Term Liabilities	$9.000K	$33.00K
YoY Change	-72.73%	-69.16%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.434M	$1.178M
Total Long-Term Liabilities	$9.000K	$33.00K
Total Liabilities	$1.443M	$1.211M
YoY Change	19.16%	16.22%
SHAREHOLDERS EQUITY
Retained Earnings	-$86.00M	-$72.53M
YoY Change	18.57%	22.85%
Common Stock	$0.00	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$40.77M	$23.15M
YoY Change
Total Liabilities & Shareholders Equity	$42.21M	$24.36M
YoY Change	73.31%	69.55%

Cashflow Statement

Concept	2022 Q1	2021 Q1
OPERATING ACTIVITIES
Net Income	-$3.508M	-$3.622M
YoY Change	-3.15%	49.36%
Depreciation, Depletion And Amortization	$6.000K	$6.000K
YoY Change	0.0%	0.0%
Cash From Operating Activities	-$3.900M	-$4.313M
YoY Change	-9.58%	44.83%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$9.000K
YoY Change	-100.0%	350.0%
Acquisitions
YoY Change
Other Investing Activities	$2.214M	$0.00
YoY Change		-100.0%
Cash From Investing Activities	$2.214M	-$9.000K
YoY Change	-24700.0%	-99.83%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00
YoY Change		-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$1.000K	$242.0K
YoY Change	-100.41%	-96.86%
NET CHANGE
Cash From Operating Activities	-$3.900M	-$4.313M
Cash From Investing Activities	$2.214M	-$9.000K
Cash From Financing Activities	-$1.000K	$242.0K
Net Change In Cash	-$1.675M	-$4.080M
YoY Change	-58.95%	599.83%
FREE CASH FLOW
Cash From Operating Activities	-$3.900M	-$4.313M
Capital Expenditures	$0.00	$9.000K
Free Cash Flow	-$3.900M	-$4.322M
YoY Change	-9.76%	45.03%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	26443067
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	26443067
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	967000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	966000	USD
CY2022Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	6000	USD
CY2022Q1	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2021Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2022Q1	us-gaap	Common Stock Shares Authorized Unlimited CommonStockSharesAuthorizedUnlimited	Unlimited
CY2021Q4	us-gaap	Common Stock Shares Authorized Unlimited CommonStockSharesAuthorizedUnlimited	Unlimited
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	433000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	509000	USD
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	26443067
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	26443067
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	26443067
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3032000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4707000	USD
CY2022Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	38015000	USD
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	40405000	USD
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	168000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	130000	USD
CY2022Q1	us-gaap	Deposits Assets Current DepositsAssetsCurrent	103000	USD
CY2021Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	113000	USD
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	793000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	84000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	42111000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	45439000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	74000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	70000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	26000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	42000	USD
CY2022Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	100000	USD
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	112000	USD
CY2022Q1	us-gaap	Assets Assets	42211000	USD
CY2021Q4	us-gaap	Assets Assets	45551000	USD
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	4000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	28000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	45000	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	1434000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1524000	USD
CY2022Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	9000	USD
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	3000	USD
CY2022Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	9000	USD
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	3000	USD
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	0	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	0	USD
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	126884000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	126576000	USD
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-107000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-51000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-86009000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-82501000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	40768000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	44024000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	42211000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	45551000	USD
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1974000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2406000	USD
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1562000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1213000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3536000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3619000	USD
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	35000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4000	USD
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	35000	USD
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4000	USD
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3501000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3615000	USD
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3508000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-3622000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-56000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-2000	USD
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3564000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3624000	USD
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	26443067
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18766656
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	44024000	USD
CY2022Q1	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	308000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-56000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3508000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	40768000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	26014000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	244000	USD
CY2021Q1	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	511000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-2000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-3622000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	23145000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3508000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-3622000	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	308000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	511000	USD
CY2022Q1	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-120000	USD
CY2021Q1	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-26000	USD
CY2022Q1	dmac	Noncash Lease Expense NoncashLeaseExpense	15000	USD
CY2021Q1	dmac	Noncash Lease Expense NoncashLeaseExpense	14000	USD
CY2022Q1	us-gaap	Depreciation Depreciation	6000	USD
CY2021Q1	us-gaap	Depreciation Depreciation	6000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	38000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3000	USD
CY2022Q1	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-10000	USD
CY2021Q1	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-0	USD
CY2022Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	709000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	383000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-76000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-410000	USD
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-16000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-458000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3888000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4313000	USD
CY2022Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	13379000	USD
CY2021Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	11923000	USD
CY2022Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	15593000	USD
CY2021Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	11921000	USD
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	-0	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9000	USD
CY2022Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2021Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	2000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2214000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9000	USD
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	244000	USD
CY2022Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	1000	USD
CY2021Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	2000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	242000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1675000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4080000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4707000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7409000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3032000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3329000	USD
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	10000	USD
CY2021Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-86000000.0	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3500000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3900000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3000000.0	USD
CY2022Q1	us-gaap	Marketable Securities MarketableSecurities	38000000.0	USD
CY2022Q1	dmac	Working Capital WorkingCapital	40700000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	40800000	USD
CY2022Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	29800000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	70000	USD
CY2022Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Concentration of credit risk</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Financial instruments that potentially expose the Company to concentration of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains its cash balances primarily with <em style="font: inherit;">two</em> financial institutions. These balances generally exceed federally insured limits. The Company has <em style="font: inherit;">not</em> experienced any losses in such accounts and believes it is <em style="font: inherit;">not</em> exposed to any significant credit risk in cash and cash equivalents. The Company believes that the credit risk related to marketable securities is limited due to the adherence to an investment policy focused on the preservation of principal.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2022Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	116000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	484000	USD
CY2022Q1	dmac	Accrued Taxes And Other Liabilities Current AccruedTaxesAndOtherLiabilitiesCurrent	8000	USD
CY2022Q1	us-gaap	Interest Receivable Current InterestReceivableCurrent	166000	USD
CY2021Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	130000	USD
CY2022Q1	us-gaap	Other Receivables OtherReceivables	2000	USD
CY2021Q4	us-gaap	Other Receivables OtherReceivables	0	USD
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	168000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	130000	USD
CY2021Q4	dmac	Accrued Taxes And Other Liabilities Current AccruedTaxesAndOtherLiabilitiesCurrent	7000	USD
CY2022Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	967000	USD
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	966000	USD
CY2022Q1	us-gaap	Deposits Assets Current DepositsAssetsCurrent	103000	USD
CY2021Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	113000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	136000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	137000	USD
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	62000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	67000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	74000	USD
CY2022Q1	dmac	Accrued Clinical Study Costs Current AccruedClinicalStudyCostsCurrent	538000	USD
CY2021Q4	dmac	Accrued Clinical Study Costs Current AccruedClinicalStudyCostsCurrent	284000	USD
CY2022Q1	dmac	Accrued Research And Professional Fees Current AccruedResearchAndProfessionalFeesCurrent	305000	USD
CY2021Q4	dmac	Accrued Research And Professional Fees Current AccruedResearchAndProfessionalFeesCurrent	191000	USD
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	16000	USD
CY2022Q1	us-gaap	Variable Lease Cost VariableLeaseCost	11000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	29000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	29000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	28000	USD
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	40000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	244000	USD
CY2021	dmac	Stock Issued During Period Shares Exercise Of Common Stock Warrants StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants	0
CY2021Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	3726911
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3508000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-3622000	USD
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	26443067
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18766656
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	308000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	511000	USD
CY2022Q1	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	2159413
CY2022Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P7Y7M6D
CY2022Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	4.88
CY2022Q1	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	1336428
CY2022Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P6Y6M

Files In Submission

Name	View Source	Status
0001437749-22-010876-index-headers.html	Edgar Link	pending
0001437749-22-010876-index.html	Edgar Link	pending
0001437749-22-010876.txt	Edgar Link	pending
0001437749-22-010876-xbrl.zip	Edgar Link	pending
dmac-20220331.xsd	Edgar Link	pending
dmac-20220331_cal.xml	Edgar Link	unprocessable
dmac-20220331_def.xml	Edgar Link	unprocessable
dmac-20220331_lab.xml	Edgar Link	unprocessable
dmac-20220331_pre.xml	Edgar Link	unprocessable
dmtp20220331_10q.htm	Edgar Link	pending
dmtp20220331_10q_htm.xml	Edgar Link	completed
ex_367015.htm	Edgar Link	pending
ex_367016.htm	Edgar Link	pending
ex_367017.htm	Edgar Link	pending
ex_367018.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
graph01.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DMAC
DiaMedica Therapeutics Inc. Stock $dmac

2022 Q1 Form 10-Q Financial Statement

#000143774922010876 Filed on May 04, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DMAC DiaMedica Therapeutics Inc. Stock $dmac

2022 Q1 Form 10-Q Financial Statement

#000143774922010876 Filed on May 04, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DMAC
DiaMedica Therapeutics Inc. Stock $dmac